Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B

Author:

Suzuki Kazuharu,Suda GokiORCID,Yamamoto Yoshiya,Abiko Satoshi,Kinoshita Kenji,Miyamoto Shuichi,Sugiura Ryo,Kimura Megumi,Maehara Osamu,Yamada Ren,Kitagataya Takashi,Shigesawa Taku,Ohara Masatsugu,Kawagishi Naoki,Nakai Masato,Sho Takuya,Natsuizaka Mitsuteru,Morikawa Kenichi,Ogawa Koji,Sakamoto Naoya

Abstract

For long-term treatment of hepatitis B virus (HBV) infection, switching from tenofovir-disoproxil-fumarate (TDF) to tenofovir-alafenamide (TAF) may prevent renal dysfunction and bone loss. However, the precise effects of this switch on the blood lipid profile remain to be clarified. This is an important issue as TDF is known to have effects on both low- and high-density lipids. Therefore, our retrospective multi-center study aimed to evaluate the effects of switching from TDF to TAF on the lipid profile of patients with HBV infection. Samples were obtained prior to the switch from TDF to TAF and at 6–12 months after TAF initiation. In some cases, additional samples obtained pre- and post-TDF administration were available for analysis. Serum cholesterol levels, including oxidized-low-density lipoprotein (LDL) and non-high-density lipoprotein-cholesterol (HDL-c), and the rate of dyslipidemia, according to the NCEP-ATP III lipid risk classification, were analyzed. The data from 69 patients were analyzed, including 33 patients with pre- and post-TDF-initiation serum samples. Total cholesterol (T-chol), HDL-c, LDL-c, non-HDL-c, and oxidized LDL levels increased significantly after switching to TAF. With regard to sequential changes pre- to post-TAF, TDF was associated with significantly lower serum T-chol, HDL-c, and oxidized LDL-c levels, with T-chol, HDL-c, LDL-c, and oxidized LDL-c levels increasing significantly after the switch. The switch from TDF to TAF was also associated with an increase in the rate of dyslipidemia, from 33% to 39%, with an increase in the rate of severe dyslipidemia of 1.4% and 5.8%, based on T-chol and LDL-c levels. Of note, no cases of severe dyslipidemia were detected pre-TAF treatment. As oxidized LDL-c and non-HDL-c are strongly associated with atherosclerosis development, careful monitoring of lipid is needed after switching from TDF to TAF in this clinical population.

Funder

Japan Agency for Medical Research and Development

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference39 articles.

1. Hepatitis B virus infection;WM Lee;N Engl J Med,1997

2. Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C;SR Walter;J Gastroenterol Hepatol,2011

3. Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection;FJ Mahoney;Clin Microbiol Rev,1999

4. JSH Guidelines for the Management of Hepatitis B Virus Infection;Drafting Committee for Hepatitis Management G, the Japan Society of H;Hepatol Res,2014

5. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection;European Association for the Study of the Liver;J Hepatol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3